DE68924783T2 - Wässrige additivsysteme, verfahren und polymerteilchen. - Google Patents

Wässrige additivsysteme, verfahren und polymerteilchen.

Info

Publication number
DE68924783T2
DE68924783T2 DE68924783T DE68924783T DE68924783T2 DE 68924783 T2 DE68924783 T2 DE 68924783T2 DE 68924783 T DE68924783 T DE 68924783T DE 68924783 T DE68924783 T DE 68924783T DE 68924783 T2 DE68924783 T2 DE 68924783T2
Authority
DE
Germany
Prior art keywords
methods
polymer particles
additive systems
aqueous additive
aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68924783T
Other languages
English (en)
Other versions
DE68924783D1 (de
Inventor
Gowsala Sivam
Michael Reed
Ananthachari Srinivasan
A Morgan
Diana Brixner
Vivekananda Vrudhula
F Comezoglu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poniard Pharmaceuticals Inc
Original Assignee
Poniard Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poniard Pharmaceuticals Inc filed Critical Poniard Pharmaceuticals Inc
Application granted granted Critical
Publication of DE68924783D1 publication Critical patent/DE68924783D1/de
Publication of DE68924783T2 publication Critical patent/DE68924783T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/402,5-Pyrrolidine-diones
    • C07D207/4042,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/203Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/24Condensed ring systems having three or more rings
    • C07H15/252Naphthacene radicals, e.g. daunomycins, adriamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
DE68924783T 1988-09-30 1989-09-29 Wässrige additivsysteme, verfahren und polymerteilchen. Expired - Fee Related DE68924783T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25229888A 1988-09-30 1988-09-30
PCT/US1989/004267 WO1990003401A1 (en) 1988-09-30 1989-09-29 Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages

Publications (2)

Publication Number Publication Date
DE68924783D1 DE68924783D1 (de) 1995-12-14
DE68924783T2 true DE68924783T2 (de) 1996-03-28

Family

ID=22955432

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68924783T Expired - Fee Related DE68924783T2 (de) 1988-09-30 1989-09-29 Wässrige additivsysteme, verfahren und polymerteilchen.

Country Status (5)

Country Link
US (1) US5633351A (de)
EP (1) EP0434765B1 (de)
JP (1) JPH04504248A (de)
DE (1) DE68924783T2 (de)
WO (1) WO1990003401A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3038339B2 (ja) * 1988-05-02 2000-05-08 ザイナクシス・テクノロジーズ・インコーポレーテッド バイオ粒子の表面膜に対してバイオアフェクティング物質を結合する化合物
US5420105A (en) * 1988-09-23 1995-05-30 Gustavson; Linda M. Polymeric carriers for non-covalent drug conjugation
GB9024176D0 (en) * 1990-11-07 1990-12-19 Medical Res Council Photolabile compounds,their synthesis and use as fluorophores
CA2048078A1 (en) * 1990-11-15 1992-05-16 Wolfgang A. Wrasidlo Chemical modification of antibodies for creation of immunoconjugates
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JPH08504824A (ja) * 1992-12-21 1996-05-28 オフィディアン ファーマシューティカルズ,インコーポレーテッド 敗血症の予防および治療
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US6460271B2 (en) 1995-04-19 2002-10-08 Csp Technologies, Inc. Insert having interconnecting channel morphology for aldehyde absorption
US6316520B1 (en) 1995-04-19 2001-11-13 Capitol Specialty Plastics, Inc. Monolithic polymer composition having a releasing material
US6194079B1 (en) 1995-04-19 2001-02-27 Capitol Specialty Plastics, Inc. Monolithic polymer composition having an absorbing material
USRE40941E1 (en) * 1995-04-19 2009-10-20 Csp Technologies, Inc. Monolithic polymer composition having a releasing material
US6174952B1 (en) 1995-04-19 2001-01-16 Capitol Specialty Plastics, Inc. Monolithic polymer composition having a water absorption material
US6221446B1 (en) 1995-04-19 2001-04-24 Capitol Specialty Plastics, Inc Modified polymers having controlled transmission rates
US6177183B1 (en) * 1995-04-19 2001-01-23 Capitol Specialty Plastics, Inc. Monolithic composition having an activation material
DE69626849T2 (de) * 1995-12-22 2003-12-24 Bristol Myers Squibb Co Verzweigte hydrazongruppen enthaltende kuppler
DE69731985T2 (de) * 1996-10-21 2005-12-29 Quadrant Drug Delivery Ltd., Ruddington Plättchen-ersatzmittel und geeignetes konjugations-herstellungsverfahren
US6465532B1 (en) 1997-03-05 2002-10-15 Csp Tecnologies, Inc. Co-continuous interconnecting channel morphology polymer having controlled gas transmission rate through the polymer
US6953675B2 (en) 1997-11-06 2005-10-11 Immunomedics, Inc. Landscaped antibodies and antibody fragments for clinical use
EP1087989A1 (de) * 1998-06-26 2001-04-04 Pfizer Products Inc. Verbessertes verfahren zur bereitstellung von schiff-basenaddukten zwischen o-hydroxyaldehyden und aminogruppen und zusammenstellungen damit erworben
WO2000038735A1 (en) 1998-12-24 2000-07-06 Kyowa Hakko Kogyo Co., Ltd. Pharmaceutical preparation
AU779473B2 (en) * 1999-10-22 2005-01-27 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Disulfide conjugated cell toxins and methods of making and using them
US7186813B1 (en) 2000-01-11 2007-03-06 Nanogen Recognomics Gmbh Biomolecules having multiple attachment moieties for binding to a substrate surface
AU2001247697B2 (en) * 2000-03-22 2006-06-22 Solulink, Incorporated Hydrazine-based and carbonyl-based bifunctional crosslinking reagents
US6696002B1 (en) 2000-03-29 2004-02-24 Capitol Security Plastics, Inc. Co-continuous interconnecting channel morphology polymer having modified surface properties
US7129229B2 (en) 2000-08-11 2006-10-31 Nanogen Recognomics Gmbh Hydrazide building blocks and hydrazide modified biomolecules
ATE550041T1 (de) * 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
JP5319278B2 (ja) * 2005-05-27 2013-10-16 ロイヤー バイオメディカル, インク. 生体再吸収性ポリマーマトリックス、ならびにその作製および使用方法
WO2007025988A2 (en) 2005-08-30 2007-03-08 Novo Nordisk Health Care Ag Liquid formulations of pegylated growth hormone
EP2040757A2 (de) 2006-07-07 2009-04-01 Novo Nordisk Health Care AG Neue proteinkonjugate und herstellungsverfahren
GB0618524D0 (en) 2006-09-20 2006-11-01 Isis Innovation Multimeric particles
WO2011015333A2 (en) 2009-08-05 2011-02-10 Philogen S.P.A. Targeting of bone marrow neovasculature
TWI506269B (zh) 2012-10-23 2015-11-01 Univ Ishou 螢光醣類衍生物之用途
US20140227208A1 (en) * 2013-02-08 2014-08-14 The Procter & Gamble Company Cosmetic compositions containing substituted azole and methods for alleviating mechanically-induced skin inflammation
US10309959B2 (en) 2014-12-03 2019-06-04 Life Technologies Corporation Charged reactive oligomers
WO2016090076A2 (en) * 2014-12-03 2016-06-09 Life Technologies Corporation Hydrazinyl and aminooxy compounds and their methods of use
WO2023137443A1 (en) * 2022-01-14 2023-07-20 Regeneron Pharmaceuticals, Inc. Verrucarin a derivatives and antibody drug conjugates thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2247163A1 (de) * 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
IL47372A (en) * 1975-05-27 1979-10-31 Yeda Res & Dev Fab'dimers bound to daunomycin or adriamycin,their preparation and pharmaceutical compositions containing same
SE441042B (sv) * 1976-09-08 1985-09-02 Pharmacia Diagnostics Ab Sett att pavisa rheumatoida faktorer
US4314987A (en) * 1979-04-04 1982-02-09 Rheumatology Diagnostics Laboratory Method for diagnosing rheumatological diseases
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
US4443426A (en) * 1982-06-14 1984-04-17 Yale University Blood agent
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
CA1336076C (en) * 1985-01-14 1995-06-27 Alan R. Fritzberg Metal radionuclide labeled proteins for diagnosis and therapy
DE3688103T2 (de) * 1985-05-17 1993-07-15 Neorx Corp Radiohalogenierte kleine molekuele fuer das markieren von proteinen.
US4868106A (en) * 1985-10-17 1989-09-19 Konishiroku Photo Industry Co., Ltd. Analytical element and method for determining a component in a test sample
CA1330378C (en) * 1986-05-08 1994-06-21 Daniel J. Coughlin Amine derivatives of folic acid analogs
US4801688A (en) * 1986-05-27 1989-01-31 Eli Lilly And Company Hydrazone immunoglobulin conjugates
WO1988002594A2 (en) * 1986-10-09 1988-04-21 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
US4735792A (en) * 1987-04-28 1988-04-05 The United States Of America As Represented By The United States Department Of Energy Radioiodinated maleimides and use as agents for radiolabeling antibodies
IL106992A (en) * 1988-02-11 1994-06-24 Bristol Myers Squibb Co Noble hydrazonic history of anthracycline and methods for their preparation
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5066789A (en) * 1988-09-30 1991-11-19 Neorx Corporation Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages

Also Published As

Publication number Publication date
EP0434765A4 (en) 1992-06-03
WO1990003401A1 (en) 1990-04-05
JPH04504248A (ja) 1992-07-30
EP0434765A1 (de) 1991-07-03
DE68924783D1 (de) 1995-12-14
EP0434765B1 (de) 1995-11-08
US5633351A (en) 1997-05-27

Similar Documents

Publication Publication Date Title
DE68924783T2 (de) Wässrige additivsysteme, verfahren und polymerteilchen.
ATE126007T1 (de) Tiererkennungssender und verfahren zu dessen herstellung.
DE3751084D1 (de) Im system programmierbare logische vorrichtung.
DE3787700T2 (de) Gleichförmige Polymerteilchen.
NO904446D0 (no) Additivkonsentrat for polymere materialer, samt fremstilling av additivkonsentratet.
DE68909999D1 (de) Modifizierte Kautschuk-Dienpolymere.
DE69003096D1 (de) Fahrzeugaufhängungssysteme.
DE3587725D1 (de) Zahnpflegemittel, Vorrichtung und Verfahren zur Lagerung und Verabreichung desselben.
FI903109A0 (fi) Polymerpartiklar innehaollande mikroporer.
DE3675543D1 (de) Kunststoffsack, verfahren und vorrichtung.
DE3677279D1 (de) Waessrige hilfsstoffzusammensetzungen, verfahren und polymerteilchen.
DE68912762D1 (de) Phasenkonjugiertes verstärkersystem und verfahren, mit vier durchfgängen.
ES296385Y (es) Perno conico.
DE68921185D1 (de) Verfahren und Zusammensetzungen zum Pelletisieren von Partikeln.
DE68920061D1 (de) Hydrofile, feine Gelpartikel und Verfahren zu deren Herstellung.
DE69020926D1 (de) Positionsservosystem und dessen Arbeitsweise.
DE58906329D1 (de) Polymerisate.
DE3687775D1 (de) Polymerpartikel und verfahren zu seiner herstellung.
DE68912515T2 (de) Granulierungsmittel und Verfahren.
DE3850489D1 (de) Fingerabdruck-Zusammensetzungen, Systeme und Verfahren.
DE68916043D1 (de) Schwellenwertnachlaufsystem.
DE58904700D1 (de) Propylen-isoblockpolymer und verfahren zu seiner herstellung.
NO890274D0 (no) Polymerer, samt fremstilling derav.
DE58909006D1 (de) Verarbeitungszusatz für halogenhaltige Polymere.
IT8919849A0 (it) Polimeri.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee